CAR-T therapy works for some blood cancers, but can we make it work for brain tumours?

July 26, 2018 by Peter Abel, The Conversation
T-cells (red) attacking cancer cells (white). Credit: Meletios Verras/

A powerful new anti-cancer therapy, called CAR-T, has shown great promise in treating blood cancers. Last year, the Food and Drug Administration approved the treatment for acute lymphoblastic leukaemia, and the results have been very promising, with remission rates of up to 83% for the very worst case patients, whose disease had returned following conventional treatments.

CAR-T (chimeric antigen receptor T-cell) therapy uses the body's immune system to destroy cancer cells. It involves taking a patient's T-cells (a type of immune cell) and genetically altering them so they attack cancer cells rather than invading organisms, such as bacteria. Large numbers of these CAR-T cells are grown in the lab before being infused into the patient.

With the recent success in mind, it is tempting to consider whether this approach would work in other cancers, particularly cancers that are notoriously difficult to treat, such as . Unfortunately, this has not happened yet, and the reason is to do with the nature of cancer itself.

Cancer is not just one disease but many, each requiring a different treatment, and tumour treatment has a dismal history, with high-grade glioblastoma patients having an average survival rate of one year after diagnosis.

Why so difficult?

So what is the problem with treating solid tumours and brain tumours in particular? The answer lies in the nature of the disease and the treatment. In leukaemia, there is a single, identifiable : a molecule on the surface of the tumour cell called CD19. It's a relatively straightforward task to engineer a CAR-T cell to attack that target and destroy the tumour.

In high-grade brain cancers (where spread and grow more quickly), the tumour is heterogeneous, which means the target molecules on the are constantly changing over the course of the disease. In different areas of the same tumour you will have different target molecules, so creating a CAR-T cell to attack the tumour becomes an impossible task.

Also, high-grade brain tumours build a network of to support and feed the tumour as it grows and spreads to other areas of the brain, in a process known as "angiogenesis". Understandably, this makes some brain tumours very difficult to treat and remove.

Another feature of brain tumours involves another type of immune cell called the regulatory T-cell. These are the cells that stop our immune system from attacking our own bodies. (When they go wrong they cause autoimmune diseases such as rheumatoid arthritis.) Brain tumours can hijack these cells to create an immunosuppressive micro-environment for the tumour to live in. Even if could get to the site of the tumour, they would be "switched off" by the actions of these regulatory T-cells, and the tumour would be safely protected from the attack.

Dismantling safe spaces

The outlook for using immunotherapy to treat brain looks poor with several barriers to be overcome, but let's look again at CAR-T therapy.

We can create a specific immune cell to attack a specific target and fourth-generation CAR-T cells can be produced to attack two or more specific targets – but this isn't enough. So instead of focusing on the moving target of the tumour cell, perhaps we should look at other targets.

The processes of angiogenesis (the development of new blood vessels) and immuno-suppression are driven by cells that have their own unique molecular characteristics, so let's target these areas. Let's take away the "safe space" the tumour has created for itself by destroying the micro-environment of the tumour, allowing our immune cells to do their job of destroying it.

There is a major problem that would need to be overcome for this to work, which is systemic toxicity – the result of the engineered CAR-T cells attacking the wrong healthy target cells. The last thing we need is for our CAR-T cells to destroy new blood vessels or all regulatory T cells.

What we need are -specific targets for the newly created blood vessels and the immune-suppressing T-. Finding these will be the focus of my future research.

Explore further: Teamwork between cells fuels aggressive childhood brain tumor

Related Stories

Teamwork between cells fuels aggressive childhood brain tumor

July 2, 2018
Scientists have discovered that cancerous cells in an aggressive type of childhood brain tumour work together to infiltrate the brain, and this finding could ultimately lead to much needed new treatments, according to a new ...

Blood vessel-forming cells involved in aggressive brain tumour

June 20, 2018
A type of highly malignant brain tumour contains a large number of cells involved in the formation of new blood vessels, helping it proliferate and spread. Targeting these cells could hinder tumour growth, according to new ...

Breaking through a tumor's defenses

June 7, 2018
In research published today, Babraham Institute researchers have shown that some tumours use not one but two levels of protection against the immune system. Knocking out one level boosted the protective effects of the second ...

Tumor-trained T cells go on patrol

May 15, 2017
'Tumour-trained' immune cells - which have the potential to kill cancer cells - have been seen moving from one tumour to another for the first time. The new findings, which were uncovered by scientists at Australia's Garvan ...

Virus could help treat advanced cancers

June 12, 2018
Early results from a small-scale clinical trial have revealed the potential of a virus to treat some advanced cancers.

New drug to supercharge immune cells in the fight against cancer

September 28, 2017
A new cancer treatment with the ability to normalise tumour blood vessels and boost the body's immune system has been developed by researchers from The University of Western Australia and the Harry Perkins Institute of Medical ...

Recommended for you

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...

Scientists have identified and modelled a distinct biology for paediatric AML

December 11, 2018
Scientists have identified and modelled a distinct biology for paediatric acute myeloid leukaemia, one of the major causes of death in children.

HER2 mutations can cause treatment resistance in metastatic ER-positive breast cancer

December 11, 2018
Metastatic breast cancers treated with hormone therapy can become treatment-resistant when they acquire mutations in the human epidermal growth factor receptor 2 (HER2) that were not present in the original tumor, reports ...

Loss of two genes drives a deadly form of colorectal cancer, reveals a potential treatment

December 11, 2018
Colorectal cancers arise from earlier growths, called polyps, found on the inner surface of the colon. Scientists are now learning that polyps use two distinct molecular pathways as they progress to cancer, called the "conventional" ...

Taking uncertainty out of cancer prognosis

December 11, 2018
A cancer diagnosis tells you that you have cancer, but how that cancer will progress is a terrifying uncertainty for most patients. Researchers at Cold Spring Harbor Laboratory (CSHL) have now identified a specific class ...

Successful anti-PD-1 therapy requires interaction between CD8+ T cells and dendritic cells

December 11, 2018
A team led by a Massachusetts General Hospital (MGH) investigator has found that successful cancer immunotherapy targeting the PD-1 molecule requires interaction between cytotoxic CD8+ T cells, which have been considered ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.